Related Experiment Video
Updated: Jun 20, 2026

Real-Time In Vitro Migration Assay for Primary Murine CD8+ T Cells
Published on: May 24, 2024
The type III TGFbeta receptor regulates directional migration: new tricks for an old dog
Abstract:
The type III transforming growth factor beta (TGFbeta) receptor (T beta RIII or betaglycan) is a TGFbeta superfamily co-receptor. Loss of T beta RIII expression occurs in a broad spectrum of human cancers including cancers of the breast, kidney, lung, ovary, pancreas and prostate. T beta RIII suppresses cancer progression, in part, by reducing cancer cell motility. This T beta RIII function is independent of its TGFbeta signaling role, with T beta RIII activating Cdc42 via its interaction with the scaffolding protein beta-arrestin2 to re-organize the actin cytoskeleton, decrease directional persistence and inhibit random migration in both epithelial-derived cancer cells and normal epithelial cells. These studies contribute to a growing body of literature supporting essential and non-redundant roles for T beta RIII and emphasize the importance of continued investigation of T beta RIII and other signaling co-receptors.
Insights
The type III transforming growth factor beta (TGFbeta) receptor (TβRIII) suppresses cancer progression by reducing cell motility, independent of its TGFbeta signaling role. This receptor reorganizes the actin cytoskeleton, inhibiting cancer cell migration.
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- Type III transforming growth factor beta (TGFbeta) receptor (TβRIII), also known as betaglycan, is a crucial co-receptor in the TGFbeta superfamily.
- Downregulation of TβRIII expression is observed in various human cancers, including breast, kidney, lung, ovarian, pancreatic, and prostate cancers.
Discussion:
- TβRIII plays a significant role in suppressing cancer progression, primarily by inhibiting cancer cell motility.
- This motility-suppressing function is distinct from TβRIII's established role in TGFbeta signaling.
- TβRIII activates Cdc42 through interaction with beta-arrestin2, leading to actin cytoskeleton re-organization, reduced directional persistence, and inhibited random migration.
Key Insights:
- TβRIII's non-canonical pathway involving Cdc42 and beta-arrestin2 is critical for suppressing epithelial cancer cell migration.
- The actin cytoskeleton re-organization mediated by TβRIII is a key mechanism for inhibiting cancer cell motility.
- Loss of TβRIII expression contributes to increased cancer cell motility and progression.
Outlook:
- Further research into TβRIII's non-signaling functions is essential for understanding its role in cancer.
- Targeting TβRIII or its associated pathways could offer novel therapeutic strategies for various cancers.
- Investigating TβRIII and other co-receptors may reveal new insights into cancer biology and treatment.
More Related Videos
09:12Efficient Retroviral Transduction and Competitive Homing for Investigating GPCR-Mediated T-Cell Localization in Diverse Tissue Microenvironments
Published on: March 28, 2025
06:15Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
Published on: September 7, 2018
Related Concept Videos
TGF - β Signaling Pathway
Cell Migration
Cell Migration
Chemotaxis and Direction of Cell Migration
Cell Polarization by Rho Proteins
Cytoskeletal Coordination in Cell Migration